Telo Genomics Corp Stock Revenue
| TELO Stock | CAD 0.12 0.01 7.69% |
Telo Genomics Corp fundamentals help investors to digest information that contributes to Telo Genomics' financial success or failures. It also enables traders to predict the movement of Telo Stock. The fundamental analysis module provides a way to measure Telo Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telo Genomics stock.
| Last Reported | Projected for Next Year |
Telo | Revenue |
Telo Genomics Corp Company Revenue Analysis
Telo Genomics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Telo Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Telo Genomics is extremely important. It helps to project a fair market value of Telo Stock properly, considering its historical fundamentals such as Revenue. Since Telo Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Telo Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Telo Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Telo Genomics Corp reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all Canada stocks is 100.0% higher than that of the company.
Telo Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telo Genomics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Telo Genomics could also be used in its relative valuation, which is a method of valuing Telo Genomics by comparing valuation metrics of similar companies.Telo Genomics is currently under evaluation in revenue category among its peers.
Telo Genomics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Telo Genomics from analyzing Telo Genomics' financial statements. These drivers represent accounts that assess Telo Genomics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Telo Genomics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.7M | 7.2M | 23.4M | 21.0M | 17.7M | 13.2M | |
| Enterprise Value | 1.9M | 6.3M | 19.8M | 18.3M | 15.1M | 12.4M |
Telo Fundamentals
| Return On Equity | -1.69 | ||||
| Return On Asset | -0.87 | ||||
| Current Valuation | 8.43 M | ||||
| Shares Outstanding | 74.56 M | ||||
| Shares Owned By Insiders | 5.34 % | ||||
| Shares Owned By Institutions | 2.74 % | ||||
| Number Of Shares Shorted | 2.46 K | ||||
| Price To Book | 16.43 X | ||||
| EBITDA | (2.79 M) | ||||
| Net Income | (2.82 M) | ||||
| Cash And Equivalents | 24.25 K | ||||
| Total Debt | 32.5 K | ||||
| Current Ratio | 0.09 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (2.63 M) | ||||
| Short Ratio | 0.07 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Beta | 1.04 | ||||
| Market Capitalization | 9.69 M | ||||
| Total Asset | 2.93 M | ||||
| Retained Earnings | (25.12 M) | ||||
| Working Capital | 2.56 M | ||||
| Net Asset | 2.93 M |
About Telo Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telo Genomics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telo Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telo Genomics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telo Stock Analysis
When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.